Table 1.
Patient characteristics.
| Patient Characteristics | General n = 44 |
Group 1—SBRT n = 26 |
Group 2—CCRT n = 18 |
p-Value |
|---|---|---|---|---|
| Gender (male, %) | 27 (61.4%) | 18 (69.2%) | 9 (50.0%) | - |
| Age (years) | 68.6 (±9.7) | 73.0 (±7.8) | 62.2 (±8.8) | <0.001 |
| BMI (kg/m2) | 26.5 (±4.3) | 26.8 (±4.9) | 26.1 (±3.5) | 0.89 |
| Active smoker (n, %) | 13/43 (30.2%) | 7/25 (28.0%) | 6/18 (33.3%) | 0.75 |
| Pack years | 39.2 (±16.4) | 43.8 (±17.3) | 32.7 (±13.0) | 0.13 |
| Diabetes (n, %) | 7 (15.9%) | 6 (23.1%) | 1 (5.6%) | 0.21 |
| COPD (n, %) | 15/35 (42.9%) | 12/21 (57.1%) | 3/14 (21.4%) | 0.046 |
| FeV1 (%) | 74.5 (±23.4) | 67.2 (±22.7) | 85.8 (±20.2) | 0.008 |
| FVC (%) | 102.8 (±20.1) | 97.9 (±18.7) | 110.2 (±20.5) | 0.098 |
| DLCO (%) | 66.6 (±20.8) | 59.8 (±20.4) | 75.9 (±17.6) | 0.034 |
| RT dose (Gy) | 55.0 (±7.7) | 49.7 (±4.3) | 63.2 (±3.1) | <0.001 |
| Pathology | ||||
| Adenocarcinoma | 21 (47.7%) | 11 (42.3%) | 10 (55.6%) | - |
| Squamous carcinoma | 15 (34.1%) | 10 (38.5%) | 5 (27.8%) | - |
| Large cell carcinoma | 1 (2.3%) | - | 1 (5.6%) | - |
| NET | 2 (4.5%) | 1 (3.8%) | 1 (5.6%) | - |
| Unspecified NSCLC | 5 (11.4) | 4 (15.4%) | 1 (5.6%) | - |
| Progressive disease (n, %) PFS (months) | 23 (52.3%) 20.2 (±12.7) |
13 (50.0%) 23.8 (±10.7) |
10 (55.6%) 15.0 (±12.8) |
0.031- |
| Median PFS (months) | 21.5 (±12.7) | 25.0 (±11.5) | 7.8 (±12.8) | 0.031 |
| Death (n, %) | 21 (47.7%) | 11 (42.3%) | 10 (55.6%) | - |
| OS (months) | 25.1 (±11.1) | 27.9 (±7.6) | 21.0 (±13.3) | 0.12 |
BMI, body mass index; CCRT, concurrent chemotherapy and radiotherapy; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity for carbon monoxide; FeV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NET, neuroendocrine tumor; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; RT, radiotherapy; SBRT, stereotactic body radiotherapy.